Anna Marie Beckmann is the Executive Vice President of Product Development at AAHI. She is responsible for guiding products through the transitional phase from pre-clinical research to evaluation in clinical trials. In the regulatory affairs arena, her group provides the necessary documentation to the U.S. Food and Drug Administration for review and approval of AAHI’s vaccine and adjuvant candidates in human clinical trials. She is also responsible for AAHI’s vaccine and adjuvant candidates in human clinical trials. She is also responsible for AAHI’s in-house pilot manufacturing facility that produces cGMP adjuvant formulations for Phase 1 vaccine clinical trials.

Anna Marie was a Senior Fellow in the STD Training Program at the University of Washington and a faculty member at the Fred Hutchinson Cancer Research Center, where her research focused on the pathogenesis of human papillomavirus infections (HPV) and the relationship between HPV infections and human anogenital cancers. In 1998 she joined Corixa Coporation as Director of Regulatory Affairs and worked on early stage clinical development of vaccines for infectious diseases and cancer. Anna Marie Beckmann earned her Ph.D. from the Department of Immunology and Infectious Diseases at Johns Hopkins University School of Public Health. Her thesis was focused on the pathobiology of infection with the human papillomaviruses JC and BK.